FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3186642624> ?p ?o ?g. }

• W3186642624 endingPage "209" @default.
• W3186642624 startingPage "195" @default.
• W3186642624 abstract "To assess the safety and effectiveness of the PRESERFLO® MicroShunt (formerly InnFocus MicroShunt) in patients with primary open-angle glaucoma (POAG). The MicroShunt, a controlled ab externo glaucoma filtration surgery device, was investigated in a 2-year, multicenter, single-arm study. Eligible patients were aged 18–85 years with POAG inadequately controlled on maximal tolerated medical therapy with intraocular pressure (IOP) ≥18 and ≤35 mmHg or when glaucoma progression warranted surgery. The MicroShunt was implanted as a stand-alone procedure with adjunctive use of topical mitomycin C (MMC; 0.2–0.4 mg/ml) for 2–3 minutes. The primary effectiveness outcome was IOP reduction and success (not requiring reoperation or pressure failures [IOP > 21 mmHg and < 20% reduction in IOP]) at year 1. Additional end points at year 2 included IOP reduction, success, glaucoma medications, adverse events (AEs), and reoperations. Results are reported in the overall population and subgroups of patients receiving 0.2 or 0.4 mg/ml MMC. In 81 patients, mean (± standard deviation [SD]) IOP decreased from 21.7 ± 3.4 mmHg at baseline to 14.5 ± 4.6 mmHg at year 1 and 14.1 ± 3.2 mmHg at year 2 (P < 0.0001). Overall success (with and without supplemental glaucoma medication use) at year 1 was 74.1%. Mean (± SD) number of medications decreased from 2.1 ± 1.3 at baseline to 0.5 ± 0.9 at year 2 (P < 0.0001), and 73.8% of patients were medication free. Most common nonserious AEs were increased IOP requiring medication or selective laser trabeculoplasty (25.9%) and mild-to-moderate keratitis (11.1%). There were 6 (7.4%) reoperations and 5 (6.2%) needlings by year 2. In an analysis (post hoc) according to MMC concentration, overall success was 78.1% (0.2 mg/ml) and 74.4% (0.4 mg/ml; P = 0.710). In the 0.2 and 0.4 mg/ml MMC groups, 51.9% and 90.3% of patients were medication free, respectively (P = 0.001). There was a trend toward lower IOP and higher medication reduction in the 0.4 mg/ml MMC subgroup. In this study, mean IOP and glaucoma medication reductions were significant and sustained over 2 years postsurgery. No long-term, sight-threatening AEs were reported. Further studies may confirm potential risk/benefits of higher MMC concentration." @default.
• W3186642624 created "2021-08-02" @default.
• W3186642624 creator A5003345723 @default.
• W3186642624 creator A5011018910 @default.
• W3186642624 creator A5016690714 @default.
• W3186642624 creator A5021707315 @default.
• W3186642624 creator A5031779275 @default.
• W3186642624 creator A5033501942 @default.
• W3186642624 creator A5041564002 @default.
• W3186642624 creator A5056675200 @default.
• W3186642624 creator A5057051248 @default.
• W3186642624 creator A5061976433 @default.
• W3186642624 creator A5067804224 @default.
• W3186642624 creator A5073952559 @default.
• W3186642624 creator A5081767868 @default.
• W3186642624 creator A5089176285 @default.
• W3186642624 date "2022-03-01" @default.
• W3186642624 modified "2023-10-18" @default.
• W3186642624 title "Safety and Effectiveness of the PRESERFLO® MicroShunt in Primary Open-Angle Glaucoma" @default.
• W3186642624 cites W1523194297 @default.
• W3186642624 cites W1532857753 @default.
• W3186642624 cites W1628148152 @default.
• W3186642624 cites W1893203835 @default.
• W3186642624 cites W1964891528 @default.
• W3186642624 cites W1973265611 @default.
• W3186642624 cites W2154392344 @default.
• W3186642624 cites W2286552028 @default.
• W3186642624 cites W2422961891 @default.
• W3186642624 cites W2745069984 @default.
• W3186642624 cites W2750960295 @default.
• W3186642624 cites W2785122589 @default.
• W3186642624 cites W2788502979 @default.
• W3186642624 cites W2921734131 @default.
• W3186642624 cites W2946563844 @default.
• W3186642624 doi "https://doi.org/10.1016/j.ogla.2021.07.008" @default.
• W3186642624 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34329772" @default.
• W3186642624 hasPublicationYear "2022" @default.
• W3186642624 type Work @default.
• W3186642624 sameAs 3186642624 @default.
• W3186642624 citedByCount "38" @default.
• W3186642624 countsByYear W31866426242021 @default.
• W3186642624 countsByYear W31866426242022 @default.
• W3186642624 countsByYear W31866426242023 @default.
• W3186642624 crossrefType "journal-article" @default.
• W3186642624 hasAuthorship W3186642624A5003345723 @default.
• W3186642624 hasAuthorship W3186642624A5011018910 @default.
• W3186642624 hasAuthorship W3186642624A5016690714 @default.
• W3186642624 hasAuthorship W3186642624A5021707315 @default.
• W3186642624 hasAuthorship W3186642624A5031779275 @default.
• W3186642624 hasAuthorship W3186642624A5033501942 @default.
• W3186642624 hasAuthorship W3186642624A5041564002 @default.
• W3186642624 hasAuthorship W3186642624A5056675200 @default.
• W3186642624 hasAuthorship W3186642624A5057051248 @default.
• W3186642624 hasAuthorship W3186642624A5061976433 @default.
• W3186642624 hasAuthorship W3186642624A5067804224 @default.
• W3186642624 hasAuthorship W3186642624A5073952559 @default.
• W3186642624 hasAuthorship W3186642624A5081767868 @default.
• W3186642624 hasAuthorship W3186642624A5089176285 @default.
• W3186642624 hasBestOaLocation W31866426241 @default.
• W3186642624 hasConcept C118487528 @default.
• W3186642624 hasConcept C126322002 @default.
• W3186642624 hasConcept C141071460 @default.
• W3186642624 hasConcept C197934379 @default.
• W3186642624 hasConcept C2776508836 @default.
• W3186642624 hasConcept C2776766258 @default.
• W3186642624 hasConcept C2777824320 @default.
• W3186642624 hasConcept C2778527774 @default.
• W3186642624 hasConcept C2781092963 @default.
• W3186642624 hasConcept C2908647359 @default.
• W3186642624 hasConcept C2991803831 @default.
• W3186642624 hasConcept C71924100 @default.
• W3186642624 hasConcept C99454951 @default.
• W3186642624 hasConceptScore W3186642624C118487528 @default.
• W3186642624 hasConceptScore W3186642624C126322002 @default.
• W3186642624 hasConceptScore W3186642624C141071460 @default.
• W3186642624 hasConceptScore W3186642624C197934379 @default.
• W3186642624 hasConceptScore W3186642624C2776508836 @default.
• W3186642624 hasConceptScore W3186642624C2776766258 @default.
• W3186642624 hasConceptScore W3186642624C2777824320 @default.
• W3186642624 hasConceptScore W3186642624C2778527774 @default.
• W3186642624 hasConceptScore W3186642624C2781092963 @default.
• W3186642624 hasConceptScore W3186642624C2908647359 @default.
• W3186642624 hasConceptScore W3186642624C2991803831 @default.
• W3186642624 hasConceptScore W3186642624C71924100 @default.
• W3186642624 hasConceptScore W3186642624C99454951 @default.
• W3186642624 hasIssue "2" @default.
• W3186642624 hasLocation W31866426241 @default.
• W3186642624 hasLocation W31866426242 @default.
• W3186642624 hasOpenAccess W3186642624 @default.
• W3186642624 hasPrimaryLocation W31866426241 @default.
• W3186642624 hasRelatedWork W1997851376 @default.
• W3186642624 hasRelatedWork W2022049485 @default.
• W3186642624 hasRelatedWork W2068363936 @default.
• W3186642624 hasRelatedWork W2081121150 @default.
• W3186642624 hasRelatedWork W2781673216 @default.
• W3186642624 hasRelatedWork W2943330015 @default.
• W3186642624 hasRelatedWork W3019109677 @default.
• W3186642624 hasRelatedWork W3032287929 @default.

• next